Current results of brachytherapy for soft tissue sarcoma

Matthew Ballo, Andrew K. Lee

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

Perioperative brachytherapy results in a better local control rate than surgery alone for extremity soft tissue sarcoma. Brachytherapy enables the delivery of a high radiation dose to a limited volume of tissue, allows the reduction of radiation treatment time, enables direct visualization of the tumor bed and surrounding critical structures, and costs less than external beam radiotherapy. The literature seems to regard the effectiveness of brachytherapy as comparable to that of external beam radiotherapy, and the side effect profile is acceptable. Traditional low-dose-rate brachytherapy methods require extended periods of patient isolation, but recent technologic advances may obviate this necessity. Newer high-dose-rate (HDR) brachytherapy delivery methods allow for the fractionation of radiation delivery and outpatient treatment in some cases. Furthermore, with HDR brachytherapy, the radiation dose distribution can be tailored around critical anatomic structures. Although the application of HDR brachytherapy to soft tissue sarcoma is relatively new, it seems to result in a satisfactory local control rate and may replace traditional low-dose-rate techniques.

Original languageEnglish (US)
Pages (from-to)313-318
Number of pages6
JournalCurrent Opinion in Oncology
Volume15
Issue number4
DOIs
StatePublished - Jul 2003
Externally publishedYes

Fingerprint

Brachytherapy
Sarcoma
Radiation
Radiotherapy
Patient Isolation
Outpatients
Extremities
Costs and Cost Analysis
Therapeutics
Neoplasms

All Science Journal Classification (ASJC) codes

  • Cancer Research

Cite this

Current results of brachytherapy for soft tissue sarcoma. / Ballo, Matthew; Lee, Andrew K.

In: Current Opinion in Oncology, Vol. 15, No. 4, 07.2003, p. 313-318.

Research output: Contribution to journalReview article

@article{53344064cc6347958f3ba51843f32cdf,
title = "Current results of brachytherapy for soft tissue sarcoma",
abstract = "Perioperative brachytherapy results in a better local control rate than surgery alone for extremity soft tissue sarcoma. Brachytherapy enables the delivery of a high radiation dose to a limited volume of tissue, allows the reduction of radiation treatment time, enables direct visualization of the tumor bed and surrounding critical structures, and costs less than external beam radiotherapy. The literature seems to regard the effectiveness of brachytherapy as comparable to that of external beam radiotherapy, and the side effect profile is acceptable. Traditional low-dose-rate brachytherapy methods require extended periods of patient isolation, but recent technologic advances may obviate this necessity. Newer high-dose-rate (HDR) brachytherapy delivery methods allow for the fractionation of radiation delivery and outpatient treatment in some cases. Furthermore, with HDR brachytherapy, the radiation dose distribution can be tailored around critical anatomic structures. Although the application of HDR brachytherapy to soft tissue sarcoma is relatively new, it seems to result in a satisfactory local control rate and may replace traditional low-dose-rate techniques.",
author = "Matthew Ballo and Lee, {Andrew K.}",
year = "2003",
month = "7",
doi = "10.1097/00001622-200307000-00006",
language = "English (US)",
volume = "15",
pages = "313--318",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Current results of brachytherapy for soft tissue sarcoma

AU - Ballo, Matthew

AU - Lee, Andrew K.

PY - 2003/7

Y1 - 2003/7

N2 - Perioperative brachytherapy results in a better local control rate than surgery alone for extremity soft tissue sarcoma. Brachytherapy enables the delivery of a high radiation dose to a limited volume of tissue, allows the reduction of radiation treatment time, enables direct visualization of the tumor bed and surrounding critical structures, and costs less than external beam radiotherapy. The literature seems to regard the effectiveness of brachytherapy as comparable to that of external beam radiotherapy, and the side effect profile is acceptable. Traditional low-dose-rate brachytherapy methods require extended periods of patient isolation, but recent technologic advances may obviate this necessity. Newer high-dose-rate (HDR) brachytherapy delivery methods allow for the fractionation of radiation delivery and outpatient treatment in some cases. Furthermore, with HDR brachytherapy, the radiation dose distribution can be tailored around critical anatomic structures. Although the application of HDR brachytherapy to soft tissue sarcoma is relatively new, it seems to result in a satisfactory local control rate and may replace traditional low-dose-rate techniques.

AB - Perioperative brachytherapy results in a better local control rate than surgery alone for extremity soft tissue sarcoma. Brachytherapy enables the delivery of a high radiation dose to a limited volume of tissue, allows the reduction of radiation treatment time, enables direct visualization of the tumor bed and surrounding critical structures, and costs less than external beam radiotherapy. The literature seems to regard the effectiveness of brachytherapy as comparable to that of external beam radiotherapy, and the side effect profile is acceptable. Traditional low-dose-rate brachytherapy methods require extended periods of patient isolation, but recent technologic advances may obviate this necessity. Newer high-dose-rate (HDR) brachytherapy delivery methods allow for the fractionation of radiation delivery and outpatient treatment in some cases. Furthermore, with HDR brachytherapy, the radiation dose distribution can be tailored around critical anatomic structures. Although the application of HDR brachytherapy to soft tissue sarcoma is relatively new, it seems to result in a satisfactory local control rate and may replace traditional low-dose-rate techniques.

UR - http://www.scopus.com/inward/record.url?scp=0041737695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041737695&partnerID=8YFLogxK

U2 - 10.1097/00001622-200307000-00006

DO - 10.1097/00001622-200307000-00006

M3 - Review article

C2 - 12874510

AN - SCOPUS:0041737695

VL - 15

SP - 313

EP - 318

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 4

ER -